Satish K Garg, George Grunberger, Ruth Weinstock, Margaret L Lawson, Irl B Hirsch, Linda A DiMeglio, Rodica Pop-Busui, Athena Philis-Tsimikas, Mark Kipnes, David R Liljenquist, Ronald L Brazg, Yogish C Kudva, Bruce A Buckingham, Janet B McGill, Anders L Carlson, Amy B Criego, Mark P Christiansen, Kevin B Kaiserman, Kurt J Griffin, Greg P Forlenza, Bruce W Bode, Robert H Slover, Ashleigh Keiter, Chenxiao Ling, Briggitte Marinos, Toni L Cordero, John Shin, Scott W Lee, Andrew S Rhinehart, Robert A Vigersky
Objective: To evaluate safety and effectiveness of MiniMed™ 670G hybrid closed loop (HCL) in comparison with continuous subcutaneous insulin infusion (CSII) therapy for 6 months in persons with type 1 diabetes (T1D). Methods: Adults (aged 18-80 years), adolescents, and children (aged 2-17 years) with T1D who were using CSII therapy were enrolled and randomized (1:1) to 6 months of HCL intervention (n = 151, mean age of 39.9 ± 19.8 years) or CSII without continuous glucose monitoring (n = 151, 35...
January 2023: Diabetes Technology & Therapeutics